ClinicalTrials.gg
RecruitingNCT05724992PROPH-ITAUpdated Feb 15, 2023

Familial Pancreatic Cancer PROPHilation Program in Italy

An interventional study of Saliva swab testing in Candidates for Hereditary Pancreatic Cancer Testing, sponsored by Associazione Italiana per lo Studio del Pancreas. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by Associazione Italiana per lo Studio del Pancreas · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,000
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies in Pancreatic Neoplasms with a site in Italy — 52 open to participants now, 76 under way, 11 of them phase 3. Pancreatic Neoplasms · Italy.

Planned enrollment
Largest of 157
3,000 · median 154
Started
2022
with 15 others
No phase
43 of 214
12 open now
Primary completion
2027-12
later than 44 of 75 live
Registered
156th of 214
by date

Among the 214 studies in Pancreatic Neoplasms with a site in Italy, this one has the largest planned enrollment of the 157 interventional ones that give a count, is one of 16 that started in 2022, is one of 43 with no phase, reaches primary completion later than 44 of the 75 other live ones, and was the 156th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

52 of the 214 studies in Pancreatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Pancreatic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only.

Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.

Up to 3,000 participants will be enrolled in this study.

03

Conditions studied

  • Candidates for Hereditary Pancreatic Cancer Testing

Keywords

  • Pancreatic Cancer
  • Pancreatic Cancer familiarity
  • Genetic profiling
  • Genetic predisposition
  • Pancreatic Cancer surveillance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being enrolled on the IRFARPC registry
  • Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
  • Willingness to participate in saliva-swab-based genetic testing

Exclusion criteria

Exclusion Criteria:

  • Already known genetic mutation
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • Other
    Saliva testing swab

    Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing

    Genetic: Saliva swab testing

Interventions

  • GeneticSaliva swab testing

    41 pancreatic cancer predisposition genes will be tested through a saliva-based swab

06

What researchers measure

Primary outcomes

  1. Presence - absence of predisposing mutations

    Prevalence of genetic mutations over the total tested

    Time frame: 5 years

Secondary outcomes

  1. Correlation of genetic mutations with personal oncological history

    Correlation between presence of predisposing mutation and prevalence of cancers

    Time frame: 5 years

  2. Correlation of genetic mutations with familial oncological history

    Correlation between presence of predisposing mutation and prevalence of cancers in the family

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
    Verona, 37136, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 60 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 60 months is above that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Feb 13, 2023
StartActual
Dec 20, 2022
Primary completionEst.
Dec 20, 2027
CompletionEst.
Dec 20, 2028
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05724992
Lead sponsor
Associazione Italiana per lo Studio del Pancreas
Collaborators
General and Pancreatic Surgery Unit, University of Verona, Fondazione Valsecchi, Associazione Oltre La Ricerca, Genomica srl
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Dec 20, 2022
Primary completion
Dec 20, 2027 (estimated)
Completion
Dec 20, 2028 (estimated)
Last update
Feb 15, 2023

Study contacts

Erica Secchettin, PharmD
Contact
familiarita.aisp@gmail.com
0458126254
AISP Association
Contact
aisp.ricerca@gmail.com
340 2713112

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion